---
schema_version: "secwatch.filing_event.v1"
accession: "0001217234-23-000043"
form_type: "8-K"
ticker: "CDNA"
cik: "0001217234"
company_name: "CareDx, Inc."
filed_at: "2023-02-27T23:59:59+00:00"
generated_at: "2026-06-18T23:14:13.268113+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CareDx Q4 revenue $82.4M (+4% YoY); net loss widens to $18.3M; guides for H1 2023 EBITDA profitability

## Summary
- Full year 2022 revenue $321.8M (+9% YoY); testing volumes up 19% to ~182,000 tests.
- Q4 net loss $18.3M ($0.34 loss per share) vs $16.2M loss in Q4 2021; non-GAAP net loss $3.7M.
- Adjusted EBITDA loss $3.7M in Q4 vs $1.4M loss; full year adjusted EBITDA loss $17.5M vs gain of $17.8M in 2021.
- Cash and marketable securities $293M, no debt; authorized $50M share buyback, repurchased $0.6M in Q4.
- Management targets adjusted EBITDA profitability in first half of 2023; ISHLT guidelines expanded use of HeartCare solutions.

## SEC filing metadata
- accession: 0001217234-23-000043
- form_type: 8-K
- ticker: CDNA
- cik: 0001217234
- company_name: CareDx, Inc.
- filed_at: 2023-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1217234/000121723423000043/0001217234-23-000043-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1217234/000121723423000043/cdna-20230227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001217234-23-000043
- JSON: https://secwatch.observer/filing/0001217234-23-000043.json
- Plain text: https://secwatch.observer/filing/0001217234-23-000043.txt

## Key facts
- Earnings Releases
  CareDx, Inc. reported full year ended December 31, 2022 results: revenue $321.8 million, net income $76.6 million, EPS $1.44.
  - Period: full year ended December 31, 2022
  - Revenue: $321.8 million
  - Net income: $76.6 million
  - EPS: $1.44
  - Result: reported results
  source text: Revenue for the full year ended December 31, 2022, was $321.8 million, an increase of 9% compared with $296.4 million in 2021. Testing services revenue for the full year ended December 31, 2022 was $263.7 million, compared with $259.3 million in 2021. Product revenue for the full year ended December 31, 2022 was $29.3 million, compared to $26.8 million in 2021. Patient and digital solutions revenue for the full year 2022 was $28.8 million, compared to $10.3 million in 2021. Net loss for the full year ended December 31, 2022 was $76.6 million, compared to a net loss of $30.7 million in 2021. Basic and diluted net loss per share for the full year ended December 31, 2022 was $1.44, compared to basic and diluted net loss per share of $0.59 in the full year ended December 31, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1217234/000121723423000043/0001217234-23-000043-index.htm
- Earnings Releases
  CareDx, Inc. reported three months ended December 31, 2022 results: revenue $82.4 million, net income $18.3 million, EPS $0.34.
  - Period: three months ended December 31, 2022
  - Revenue: $82.4 million
  - Net income: $18.3 million
  - EPS: $0.34
  - Result: reported results
  source text: Revenue for the three months ended December 31, 2022 was $82.4 million, an increase of 4% compared with $79.2 million in the fourth quarter of 2021. Testing services revenue for the quarter was $65.4 million, compared with $68.7 million in the same period in 2021. Total AlloSure ® and AlloMap ® patient results provided in the quarter were 47,700, including 2,300 AlloSure ® Lung patient results. Product revenue in the three months ended December 31, 2022 was $8.6 million, compared to $7.7 million in the same period in 2021. Patient and digital solutions revenue in the fourth quarter of 2022 was $8.4 million, compared to $2.9 million in the same period in 2021. For the fourth quarter of 2022, net loss was $18.3 million, compared to a net loss of $16.2 million in the same period in 2021. Basic and diluted net loss per share in the fourth quarter of 2022 was $0.34, compared to basic and diluted net loss per share of $0.31 in the fourth quarter of 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1217234/000121723423000043/0001217234-23-000043-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.